Alaproclate--an open clinical study in depressive illness

Area of Science:

• Pharmacology
• Psychiatry
• Clinical Medicine

Background:

• Depression is a significant global health burden.
• Treatment-resistant depression (TRD) poses a therapeutic challenge.
• Alaproclate is being investigated for its antidepressant properties.

Purpose of the Study:

• To evaluate the antidepressant efficacy of alaproclate in a chronic, drug-resistant depressive population.
• To explore the biochemical correlates of treatment response to alaproclate.
• To assess the safety and tolerability of alaproclate in this patient group.

Main Methods:

• An open-label study design was employed.
• Patients with chronic and drug-resistant depression were enrolled.
• Hamilton Rating Scale for Depression (HRSD) scores and biochemical parameters (Km, 5-HT, plasma drug levels) were monitored.

Main Results:

• Alaproclate demonstrated a notable antidepressant effect, with significant improvements in HRSD scores for responders.
• Biochemical analysis indicated distinct biological profiles between responders and non-responders.
• Increases in Km values correlated with treatment response and plasma drug levels, suggesting a pharmacodynamic effect.
• Mild side effects (anticholinergic, liver function abnormalities, fecal occult blood) were observed but generally manageable.

Conclusions:

• Alaproclate exhibits promising antidepressant activity in a difficult-to-treat patient population.
• Biochemical markers may help identify patients likely to respond to alaproclate.
• Further controlled clinical trials are recommended to confirm efficacy and optimize treatment with alaproclate.